
EXCLUSIVE I died after giving birth...The vision I had before doctors saved me shook my faith in the afterlife
Samantha had an uneventful pregnancy and delivery eight months ago, so it shocked everyone when she had a life-threatening complication four weeks later.
In October 2024, a month after welcoming her baby, Zuma, she began to bleed profusely, eventually losing four liters of blood, almost everything in her body.
As doctors rushed to save her life, her eyes closed, and everything faded to black. She could feel herself dying.
'It was silent and dark, and I was just simply at peace,' she said. 'I didn't feel anything, and in my mind, I knew that I was dying, but I wasn't scared. It felt like I was just going to sleep.'
In that moment, she didn't see the tunnel of light or deceased loved ones she was expecting, but she felt an immense peace take over.
Doctors found that Samantha had a pseudoaneurysm – a collection of blood outside of a blood vessel, which, given the proximity to her C-section, was considered a delayed postpartum hemorrhage - or excessive bleeding after birth.
Samantha spent a week in the ICU following the emergency, missing some of the early days of her daughter's life as she slowly recovered from the ordeal.
'Once I was aware enough to realize that I was in the ICU, and that my daughter wasn't with me, it was so sad,' she said: 'She was only four weeks old and we both needed each other – we were still in the new mommy/baby phase and we were bonding. I just wanted to see her and hold her.'
Samantha's pregnancy and most of her labor had gone smoothly, but an emergency C-section was needed when her baby's heart rate dropped.
Although she experienced minor bleeding after the surgery, she recovered well. However, four weeks later — the morning after she and her husband marked the anniversary of their first date — she woke up in a terrifying condition.
She said: 'I woke up at 5am to a wet, gushing feeling. I looked down and was absolutely covered in blood. My shorts and legs were soaked, and the blood had also soaked through my sheets, mattress topper, and mattress.
'Because I had already hemorrhaged in the hospital, I knew what was happening. This time was just so much worse.'
At the hospital, doctors rushed her into surgery and administered multiple blood transfusions while she fell in and out of consciousness.
'Apparently, at some point, the bleeding got worse and I began to crash,' she said. 'My pulse dropped down to 52, my hemoglobin level dropped to a three, a crash cart was brought out, and I just knew that I was dying.
'In an awake state during this, I shouted out to my husband that I loved him more than anything and to take care of our new baby.'
That was the moment she felt her life slipping away.
While Samantha was unconscious, doctors rushed her into surgery. They found a blockage and weakened blood vessel (an aneurysm) in her right uterine artery, which was causing the bleeding.
To stop it, they performed a procedure called a Bilateral Uterine Artery Embolisation — where the blood supply to the uterus is deliberately reduced — using an absorbable sponge to block the artery, like a temporary cork.
A surgeon was kept on standby in case an emergency hysterectomy (removal of the uterus) was needed, something Samantha and her husband, Louie, hoped to avoid to preserve their chance of having more children.
The four-hour surgery worked, but Samantha spent a week in intensive care, missing some of her baby's early days as she recovered.
'Once I was aware enough to realize that I was in the ICU, and that my daughter wasn't with me, it was so sad,' she added.
'I kept asking my husband to bring her to see me, but we decided together that she shouldn't be coming to the ICU around all those germs. Coming home was the best feeling ever.'
Samantha described the lasting trauma she experienced after the ordeal, saying she struggled with severe PTSD. For months, she barely ate or slept, was plagued by nightmares, and felt anxious about being too far from the hospital in case she started bleeding again.
She cried daily, suffered frequent panic and anxiety attacks, and constantly checked for signs of bleeding, sometimes even feeling phantom sensations.
In the months that followed, she underwent several scans to ensure no new aneurysms had developed, and after six months, her blood count finally returned to normal.
Still, the experience left her fearful about the risks of future pregnancies and whether something similar could happen again.
'I want more babies, and because my case was so rare, I don't really have answers,' she said.
'Could this happen to me again? Yes. Could this happen during a future pregnancy? Yes. Was this aneurysm brought on because of my pregnancy? Nobody knows.'
A hemorrhage is relatively rare, affecting 0.2 percent to 2.5 percent of postpartum women.
After all she has been through, the artist has a whole new appreciation for life that she is taking with her into the future.
'I know it is so cliché, but this gave me a new perspective on life. I feel like I am a lot more chill, and things really don't bother me as much, because I know what could have been,' she said.
'So what if I'm stuck in traffic or if my phone dies – I'm alive!'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
an hour ago
- Reuters
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
June 20 (Reuters) - Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly (LLY.N), opens new tab and Novo Nordisk ( opens new tab could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron (REGN.O), opens new tab and Scholar Rock (SRRK.O), opens new tab. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035.


Telegraph
2 hours ago
- Telegraph
NHS could face cuts under assisted dying law, warns Streeting
NHS services could face cuts to cover the cost of carrying out assisted deaths, the Health Secretary has warned. Under the Bill passed on Friday, the NHS will be expected to carry out the assisted dying procedures. Analysis suggests that implementation of assisted dying may cost the health service close to half a billion pounds within a decade, with each death costing the taxpayer more than £15,000. Assisted dying is set to be legalised in England and Wales after a historic vote saw it voted through by a majority of 23 MPs. However, Wes Streeting – who voted against the Bill – is understood to be deeply concerned about the impact it might have on an overstretched NHS. Speaking ahead of the vote, he warned: 'There isn't money allocated to set up the service in the Bill', while stressing that the Government would respect the decision of the House. Previously, he had warned there would be 'choices and trade-offs' to make, saying 'any new service comes at the expense of other competing pressures and priorities'. Last week, the Health Secretary said the NHS was 'in a fight for its life' as he described his mission to turn the service around. A number of MPs who opposed the Bill have raised concerns that assisted dying could take resources away from patients. On Tuesday, Dame Siobhain McDonagh, a Labour MP who voted against the legislation, said it could become 'the Trojan horse that breaks the NHS', saying it would 'rob our stretched NHS of much-needed resources'. The impact assessment of the Terminally Ill Adults (End of Life) Bill estimates that up to 28,317 people will die by state assisted suicide within the first 10 years of rollout. This rises from 647 in year one to more than 4,500 by 2038, and could mean costs of £429 million for the NHS over the decade. The spending includes educating all health and social care staff, training the doctors and nurses involved in the assisted dying service, setting up a regulator, as well as the costs of the lethal drugs themselves. Training staff is set to be the biggest cost – especially as the service is created. This could cost up to £35.5 million in the first year if all involved got the highest level of training available with no one opting out. There would then be recurring annual costs of between £10-22 million. Staff costs could reach £72 million over 10 years, with up to seven staff working for 32 hours per assisted death, it concludes. None of the calculations include the lost productivity and knock-on effects of the work the doctors are no longer able to carry out as a result. The impact assessment puts the cost of the drugs required at around £15 per person. However, independent experts have said it is highly likely to cost more. The Government also predicts a regulator and panel to assess cases would cost up to £13.6 million every year to run. The assessment suggests that overall, the Government could save money as a result of the earlier deaths, with overall savings of more than £640 million. Some of these savings could be made by the NHS. By 2038, health services could save up to £71.5 million a year on end-of-life care, because of the savings from not providing costly hospital care for cancer. Assisted dying is now on course to be available by 2029. Adults with a terminal illness and less than six months to live will be eligible under the new law. The law passed despite widespread opposition, with opponents raising concerns over the dropping of a requirement for a High Court judge to sign off on all assisted dying cases. Critics also warned that the law would 'normalise the choice of death over life, care, respect and love'.


Daily Mail
3 hours ago
- Daily Mail
EXCLUSIVE I ignored all the signs... then doctors found an aggressive cancer. Here is what I wish I knew
An Oregon man who blamed his extreme fatigue and weight loss on work stress actually had terminal cancer. Once an ultramarathon champion and self-proclaimed 'health nut,' the 41-year-old had grown accustomed to intense weight training and running up to five miles a day. He mostly steered clear of alcohol and processed foods and prioritized a balanced diet with all organic vegetables and lean proteins. But earlier this year, he noticed he could no longer get through his regular exercise routine - 'the first big change' that signaled a deadly issue. Over the course of several months, he suffered extreme fatigue and dropped 30 pounds without trying. 'I thought it was just stress at work,' the mechanical engineer said. However, bloodwork and an abdominal CT at his yearly checkup revealed stage four pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Just one in eight patients with pancreatic cancer is expected to survive five years, data shows, and when it's diagnosed in later stages, which happens most of the time, survival rates dwindle to just three percent. The man, who posted his story in an anonymous Reddit thread, has just six months left to live despite living 'a very healthy lifestyle' and having no family history of the disease. He said: 'I never smoked, almost never drank, ate clean and exercised daily. Sometimes biology lets you down.' Pancreatic cancer affects roughly 67,000 Americans every year and kills about 52,000. More than half the time, the disease is first spotted after it has already reached stage three or four due to its vague symptoms. These include abdominal pain, weight loss, back pain, jaundice and floating or clay-colored stools. This leads patients to assume their symptoms are from more benign causes like irritable bowel syndrome (IBS). This was the case for Clair Honeywood, a 45-year-old from the UK who chocked her severe stomach pain up to IBS. She was diagnosed with inoperable pancreatic cancer and given a year to live. And Matthew Rosenblum of Michigan assumed his bone-white stools in 2021 were from Crohn's disease, but it was actually stage four pancreatic cancer at age 32. It's unclear exactly what causes pancreatic cancer, but smoking, obesity and diabetes are thought to increase the risk by inducing harmful inflammation that causes cells to divide and become mutated more easily. The man in the Reddit thread, however, blames his diagnosis on bad luck. He said: 'Before this diagnosis, I was in perfect health. I thought I had another 50 years left. The first thought was 'This is too soon.'' The former engineer said he will soon move into hospice care and try psilocybin therapy for pain and the mental health effects that have come with his diagnosis. Psilocybin, the psychoactive ingredient in magic mushrooms, has been thought to reduce anxiety and depression in cancer patients. He also has signed up for several clinical trials. It's unclear if he will be getting standard treatments like chemotherapy or radiation. For now, he is focusing on using up his savings on vacations, scuba diving, skydiving and other items on his bucket list. His main regret is not taking enough risks like 'starting a business, moving to another place, trying something you were interested in but didn't know if you could do.' 'In the end, your failures are often not as consequential as you might think,' he added. He said: 'I'm glad I've been able to experience life. In all the possible realities I could've existed in, this was a pretty good one. Even if it's short. 'I don't have any grandiose aspirations for my legacy. A simple 'that guy was alright' is good enough for me. 'The biggest piece of advice I would give is to not take the time you have for granted. I know that's probably a worn out statement, but it rings incredibly true when you realize how finite your life really is.'